-
Mashup Score: 0
Responses in 37% of patients previously treated with anti-PD-1/L1 agents, platinum chemotherapy
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0
Chemotherapy regimens with higher cumulative dose provide greatest benefit
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Meta-analysis shows combining #anthracycline and #taxane for early-stage operable #breastcancer was more effective than either anthracycline or taxane #chemotherapy alone in reducing breast cancer recurrence and death. #OncoTwitter #MedTwitter https://t.co/girOedufaZ
-
-
Mashup Score: 0
Caregivers of those with other conditions also see consequences
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
"We note that these differences were persistent and that caregivers did not return to their precaregiving financial situations, which potentially sets them up for long-term financial strain." --@CathyjBradley. #OncoTwitter https://t.co/871DkPGbc2
-
-
Mashup Score: 0
Carcinogenic associations between obesity and cancer risk are reversible, study authors suggest
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Researchers have found that bariatric surgery for women with #obesity was associated with a reduction in #breastcancer risk that reached levels seen among those with a normal #BMI. #OncoTwitter https://t.co/JV2hjTpsZL
-
-
Mashup Score: 0Older Men Still Overscreened for Prostate Cancer, Survey Says - 1 year(s) ago
PSA screening rates over 50% for men 70 and up, despite USPSTF recommendations against it
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Older men are being overscreened for #prostatecancer, despite USPSTF guidelines against #PSA testing in men ages 70 and up, a survey study showed. #OncoTwitter https://t.co/ZVr24tD14t
-
-
Mashup Score: 0SYK Inhibitor Promising in Early Trial of Primary ITP - 1 year(s) ago
Sovleplenib demonstrated ‘consistent response’ as second-line treatment
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
An investigational selective spleen tyrosine kinase inhibitor was well tolerated and induced durable responses as second-line therapy for #ITP, a study from China showed. #OncoTwitter #SYK #MedTwitter https://t.co/ZiE2rD5ZLb
-
-
Mashup Score: 0CAR T-Cell Therapy Feasible, Safe in Advanced Neuroblastoma - 1 year(s) ago
ORR of 63% with GD2-targeting product in kids with relapsed, refractory high-risk disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#Immunotherapy with a #CAR T-cell treatment targeting #GD2 may have a sustained #antitumor effect in at least a proportion of #pediatric patients with relapsed or refractory high-risk #neuroblastoma, as well as a favorable safety profile. #OncoTwitter https://t.co/RVDeJL4ro9
-
-
Mashup Score: 1Leading Causes of Death Hit Childhood Cancer Survivors Earlier - 1 year(s) ago
But excess risk lowest in survivors with a healthy lifestyle
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
A report from the Childhood Cancer Survivor Study showed #survivors of #childhoodcancer had a fourfold higher risk of #mortality decades after their #diagnosis, typically from the same leading causes of #death afflicting the general U.S. population. https://t.co/YZ9MlnLf7s
-
-
Mashup Score: 0A 'Double Whammy' for Gastric Cancer Risk - 1 year(s) ago
H. pylori infection and certain pathogenic variants linked with large excess risk
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
"Our results suggest that in persons known to carry a #pathogenic variant in a homologous-recombination #gene, evaluation and eradication of #Hpylori infection may be particularly important," wrote Yukihide Momozawa, DVM, PhD, of @RIKEN_IMS. #OncoTwitter https://t.co/ruFQY0VWqn
-
-
Mashup Score: 0Cancer Plan Has Big Goal; Boosting Advanced-Care Planning; Elephant Genes for Cancer - 1 year(s) ago
News, features, and commentary about cancer-related issues
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Hey #OncoTwitter! Here's what you may have missed this week: https://t.co/hKxiKGdGg9 (Thread)
-
A preliminary clinical trial showed that more than a third of patients with previously treated head and neck #cancer responded to a novel bispecific #antibody. #AACR23 #AACR2023 @AACR https://t.co/KDb5qgGlMf